StockNow
Log in
U.S. Markets

Eli Lilly (LLY) to acquire AtaiBeckley (ATAI) to advance therapies for treatment-resistant depression and other mental health conditions; deal value at USD 6.75/shr upfront

StockNow breaking-news AI analysis

Eli Lilly acquires AtaiBeckley for $6.75/share to secure a leading position in the psychedelic medicine market, leveraging favorable regulatory shifts and a breakthrough-designated depression pipeline.

2 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement